menu
    • menu
    [{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"PRT543","moa":"PRMT5","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"PRT1419","moa":"Mcl-1","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"PRT3645","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Preclinical","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"PRT3789","moa":"SMARCA2 protein","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"PRT2527","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ BeiGene","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"PRT2527","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ AbCellera","highestDevelopmentStatusID":"2","companyTruncated":"Prelude Therapeutics \/ AbCellera"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"PRT3789","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prelude Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Prelude Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Prelude Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Docetaxel","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"Prelude Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"PRT3789","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Prelude Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Prelude Therapeutics","sponsor":"Pathos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"PRT811","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Prelude Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Prelude Therapeutics \/ Pathos","highestDevelopmentStatusID":"12","companyTruncated":"Prelude Therapeutics \/ Pathos"}]

    Find Clinical Drug Pipeline Developments & Deals by Prelude Therapeutics

    Menu

    Prelude Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prelude Therapeutics’ PRT3789 Shows Promising Clinical Activity in Phase 1 Trial

                            Details : PRT3789 is a potent and highly selective SMARCA2 degrader, it is being investigated to treat cancer patients with a SMARCA4 mutations.

                            Brand Name : PRT3789

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 13, 2024

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT811

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pathos Expands Pipeline with License of Phase 2-ready PRMT5 Inhibitor

                            Details : Through the license agreement, Pathos will gain the exclusive rights of the Phase 2-ready Brain-penetrant, PRMT5 Inhibitor, P-500 (PRT811) for treating solid tumors including high-grade glioma.

                            Brand Name : P-500

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : PRT811

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pathos

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT3789,Docetaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prelude and Merck to Evaluate PRT3789 with KEYTRUDA® for SMARCA4-Mutated Cancers

                            Details : Prelude PRT3789, a potent and highly selective, SMARCA2 degrader, is currently advancing in a clinical trial in combination with KEYTRUDA (pembrolizumab) for patients with SMARCA4-mutated cancers.

                            Brand Name : PRT3789

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 09, 2024

                            Lead Product(s) : PRT3789,Docetaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Announces $25 Million Private Placement

                            Details : The company intends to use the net proceeds to primarily fund the continued advancement of its SMARCA2 portfolio, including its IV molecule, PRT3789, a potent and highly selective SMARCA2 degrader.

                            Brand Name : PRT3789

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 11, 2023

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $25.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjuga...

                            Details : Under the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize potentially first-in-class treatments for patients with cancer by combining deep expertise in antibody and small molecule development to create precision ADC the...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : AbCellera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT2527

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Announces Pricing of Public Offering

                            Details : The net proceeds of the offering will advance company's current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789, advance its research and discovery efforts including its efforts for a new SMARCA2 oral molecule.

                            Brand Name : PRT2527

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 18, 2023

                            Lead Product(s) : PRT2527

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT2527

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Announces Launch of Proposed Public Offering

                            Details : Prelude intends to use the net proceeds to advance its current clinical pipeline, including PRT2527, PRT1419, PRT3645 and PRT3789 and advance its research and discovery efforts including its efforts for a new SMARCA2 oral molecule.

                            Brand Name : PRT2527

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 17, 2023

                            Lead Product(s) : PRT2527

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Morgan Stanley

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT2527,Zanubrutinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BeiGene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination wi...

                            Details : Under the agreement, BeiGene will provide zanubrutinib to Prelude and will collaborate for future evaluation of Prelude's investigational CDK9 inhibitor, PRT2527, in combination with it’s BTK inhibitor, zanubrutinib, in hematologic malignancies.

                            Brand Name : PRT2527

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : PRT2527,Zanubrutinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BeiGene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 ...

                            Details : PRT3789 is a Potent and Selective First-in-Class SMARCA2 Protein Degrader. Preclinical models demonstrated that selective degradation of SMARCA2 with potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolera...

                            Brand Name : PRT3789

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2022

                            Lead Product(s) : PRT3789

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Prelude Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRT3645

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcomi...

                            Details : PRT3645 is a highly potent, selective and brain penetrant CDK4/6 inhibitor that demonstrated greater than 10x brain penetration compared to approved CDK4/6 agents in preclinical models. Prelude intends to develop PRT3645 in the underserved cancers.

                            Brand Name : PRT3645

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : PRT3645

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth